Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
NRx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders.
Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.
The company has a joint Agreement with Nephron Pharmaceuticals, Inc. to develop intravenous ketamine to treat suicidal depression.
The company was founded in 2015 and is based in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.50 Decreased by -212.50% | -0.37 Decreased by -35.14% |
| Mar 29, 24 | -0.50 Decreased by -212.50% | -0.70 Increased by +28.57% |
| Nov 13, 23 | -0.07 Increased by +50.00% | -0.11 Increased by +36.36% |
| Aug 14, 23 | -0.12 Decreased by -9.09% | -0.14 Increased by +14.29% |
| May 15, 23 | -0.16 Increased by +23.81% | -0.14 Decreased by -14.29% |
| Mar 31, 23 | -0.16 Increased by +69.81% | -0.14 Decreased by -14.29% |
| Nov 14, 22 | -0.14 Increased by +65.00% | -0.14 |
| Aug 15, 22 | -0.11 Increased by +98.31% | -0.10 Decreased by -10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -6.06 M Increased by +32.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.72 M Decreased by -99.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.64 M Decreased by -12.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -5.72 M Increased by +81.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.03 M Increased by +56.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -4.36 M Increased by +72.74% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -11.19 M Increased by +75.20% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -30.79 M Decreased by -2.73 K% | Decreased by N/A% - |